Cytomegalovirus infection
CMV mononucleosis in the immunocompetent, end-organ disease in transplant and advanced HIV, quantitative PCR versus biopsy, ganciclovir and its alternatives, and who is at highest risk after solid organ versus stem cell transplant.
Tier 2Condition
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
At a glance
- CMV (human herpesvirus 5) infects most adults and stays latent for life in myeloid cells. Disease comes from primary infection, reactivation or reinfection.
- Immunocompetent: a heterophile-negative mononucleosis that settles without treatment.
- Immunocompromised: end-organ disease (colitis, pneumonitis, hepatitis, retinitis), plus indirect effects such as graft rejection.
Loading the rest of the note…
Finished reading?
Sources
- Therapeutic Guidelines: Antibiotic (cytomegalovirus infection)AU/NZTherapeutic Guidelines Limited
- Kotton CN, Kumar D, Manuel O et al. The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation 2025;109(7):1066-110The Transplantation Society International CMV Consensus Group, 2025
- Ljungman P et al. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies (ECIL 10). Lancet Infect Dis 2025;25(8):e451-62European Conference on Infections in Leukaemia, 2025 (replaces ECIL 7, 2019)
- Russo D et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection. Lancet Haematol 2024;11(2):e127-35The Lancet Haematology, 2024
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Cytomegalovirus diseaseUS Department of Health and Human Services (NIH, CDC, HIVMA/IDSA), Living guideline, accessed November 2026
- PBS item 14856X: maribavir (Livtencity) 200 mg tablet, Section 100 HSD (public), Authority Required (Streamlined), cytomegalovirus infection and diseaseAU/NZPharmaceutical Benefits Scheme, Australian Government, Accessed November 2026
- Prevymis (letermovir) prescribing information: kidney transplant (D+/R-) and allogeneic HSCT prophylaxis, dosing with ciclosporin, interactionsUS Food and Drug Administration (DailyMed), Accessed November 2026
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback